Abstract |
Clinical management of abdominal aortic aneurysm (AAA) is currently limited to elective surgical repair because an effective pharmacotherapy is still awaited. Inhibition of histone deacetylase (HDAC) activity could be a promising therapeutic option in cardiovascular diseases. We aimed to characterise HDAC expression in human AAA and to evaluate the therapeutic potential of class I and IIa HDAC inhibitors in the AAA model of angiotensin II (Ang II)-infused apolipoprotein-E-deficient ( ApoE(-/-)) mice. Real-time PCR, western blot and immunohistochemistry evidenced an increased expression of HDACs 1, 2 (both class I), 4 and 7 (both class IIa) in abdominal aorta samples from patients undergoing AAA open repair (n=22) compared with those from donors (n=14). Aortic aneurysms from Ang-II-infused ApoE(-/-) mice exhibited a similar HDAC expression profile. In these animals, treatment with a class I HDAC inhibitor (MS-275) or a class IIa inhibitor (MC-1568) improved survival, reduced the incidence and severity of AAA and limited aneurysmal expansion evaluated by Doppler ultrasonography. These beneficial effects were more potent in MC-1568-treated mice. The disorganisation of elastin and collagen fibres and lymphocyte and macrophage infiltration were effectively reduced by both inhibitors. Additionally, HDAC inhibition attenuated the exacerbated expression of pro-inflammatory markers and the increase in metalloproteinase-2 and -9 activity induced by Ang II in this model. Therefore, our data evidence that HDAC expression is deregulated in human AAA and that class-selective HDAC inhibitors limit aneurysm expansion in an AAA mouse model. New-generation HDAC inhibitors represent a promising therapeutic approach to overcome human aneurysm progression.
|
Authors | María Galán, Saray Varona, Mar Orriols, José Antonio Rodríguez, Silvia Aguiló, Jaume Dilmé, Mercedes Camacho, José Martínez-González, Cristina Rodriguez |
Journal | Disease models & mechanisms
(Dis Model Mech)
Vol. 9
Issue 5
Pg. 541-52
(05 01 2016)
ISSN: 1754-8411 [Electronic] England |
PMID | 26989193
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016. Published by The Company of Biologists Ltd. |
Chemical References |
- Apolipoproteins E
- Biomarkers
- Histone Deacetylase Inhibitors
- Angiotensin II
- Collagen
- Elastin
- Matrix Metalloproteinase 2
- Matrix Metalloproteinase 9
- Histone Deacetylases
|
Topics |
- Angiotensin II
- Animals
- Aorta, Abdominal
(drug effects, pathology)
- Aortic Aneurysm, Abdominal
(drug therapy, enzymology)
- Apolipoproteins E
(deficiency, metabolism)
- Biomarkers
(metabolism)
- Collagen
(metabolism)
- Disease Models, Animal
- Disease Progression
- Elastin
(metabolism)
- Enzyme Induction
(drug effects)
- Female
- Histone Deacetylase Inhibitors
(pharmacology, therapeutic use)
- Histone Deacetylases
(biosynthesis, metabolism)
- Humans
- Inflammation
(pathology)
- Male
- Matrix Metalloproteinase 2
(metabolism)
- Matrix Metalloproteinase 9
(metabolism)
- Middle Aged
- Severity of Illness Index
- Up-Regulation
(drug effects)
|